QV Bioelectronics has received funding from the UK’s innovation agency, Innovate UK to continue developing our life-extending treatment option for terminal cancer patients.
The Manchester based start-up has received co-funding from the UK’s innovation agency, Innovate UK to support further device development. Funding from Innovate UK’s SMART scheme will assist QV Bioelectronics in further prototyping, materials investigations and for in vitro studies. Additionally, the funding will help to strengthen their intellectual property rights while also aiding commercial development.
Innovate UK will be co-funding a £115k project, so we can move one step closer to improving the outcomes and the quality of life of glioblastoma patients.